Eli Lilly, the drugmaker behind the GLP-1 drugs Mounjaro and Zepbound, will allow a limited number of adults with severe obesity to seek early access to retatrutide, its experimental weight loss drug, according to original reporting from STAT , a health and life science news publication.

The decision comes after STAT revealed that the company had provided the unapproved medication to an anonymous 79-year-old adult through a “compassionate use” pathway allowed by the U.S. Food and Drug Administration (FDA).

This doesn’t mean retatrutide is now broadly available to the public. The once-weekly injection, which targets three hormone receptors in…

Read the full article at EVERYDAYHEALTH.COM